Equities researchers at Leerink Partnrs boosted their Q2 2025 earnings estimates for shares of Twist Bioscience in a research ...

Leerink upgraded Doximity (DOCS) to Outperform from Market Perform with a price target of $90, up from $60. While “admittedly late on this,” ...

An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied promised bonuses and deferred grant awards worth millions of dollars.

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Free Report) have been given an average recommendation of “Buy” by the nine brokerages that are covering the stock, MarketBeat.com reports.

What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street’s best analysts ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

Chair and CEO of Insmed Inc. (NASDAQ:INSM), recently executed a significant stock transaction amid the company's impressive 178% stock surge over the past year. According to a recent SEC filing, Lewis ...

The company built a digital platform for medical professionals that helps carry out telehealth appointments with patients, ...

Michael Alexander Smith, the Chief Legal Officer of Insmed Inc. (NASDAQ:INSM), has recently sold a significant portion of his holdings in the company. According to a recent SEC filing, Smith sold ...

Q4 2024. Management View. CEO Mark Tarr emphasized strong financial performance in Q4 2024, with revenue increasing ...